The FDA approved gedatolisib with fulvestrant, with or without palbociclib, for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected after...
On November 10, the U.S. Department of Health and Human Services announced that the FDA is initiating the removal of certain black box warnings from hormone replacement therapy products for menopause,...
NPS Pharmaceuticals Inc's hormone replacement therapy Natpara appears effective, though data from one clinical trial site was excluded due to manufacturing violations, according to a preliminary report...
